HomeTagsOrelabrutinib

Orelabrutinib

Biotechnology

InnoCare Announces Review of Orelabrutinib for the Treatment of R/R MZL by NMPA

Business Wire - September 6, 2022

InnoCare Pharma, a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that BTK inhibitor orelabrutinib has been granted priority review...

Biotechnology

InnoCare Announces Approval of Phase II Clinical Trial Using Orelabrutinib for the Treatment of NMOSD in China

PR Newswire - March 2, 2022

InnoCare Pharma, a leading biopharmaceutical company, announced the Investigational New Drug (IND) approval of its Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib by China National...